Selected research
Industry Research
Angiogenesis Therapeutic Agent Industry Research Report 2026
Market perspective
The global Angiogenesis Therapeutic Agent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Angiogenesis Therapeutic Agent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Angiogenesis Therapeutic Agent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Angiogenesis Therapeutic Agent include Sun Pharma, Shanghai Pharmaceuticals, Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Pfizer, Daiichi Sankyo, Bayer AG and The Geuder Group, MORCHER GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Angiogenesis Therapeutic Agent market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Angiogenesis Therapeutic Agent Market by Company
Sun Pharma
Shanghai Pharmaceuticals
Johnson & Johnson
Novartis AG
Gilead Sciences, Inc.
Pfizer
Daiichi Sankyo
Bayer AG
The Geuder Group, MORCHER GmbH
Santen Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals, Inc.
Otsuka Pharmaceutical Co. Ltd
Novamedika
Medicom Health care
Implandata ophthalmic products GmbH
Genentech, Inc.
Eyetech Inc.
ERC Labs
Becton, Dickinson and Company
Allergan plc
Angiogenesis Therapeutic Agent Segment by Type
Diabetic Retinopathy
Myopic Choroidal Neovascularization
Macular Edema
Macular Degeneration
Angiogenesis Therapeutic Agent Segment by Application
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Angiogenesis Therapeutic Agent Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiogenesis Therapeutic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angiogenesis Therapeutic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiogenesis Therapeutic Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Angiogenesis Therapeutic Agent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Angiogenesis Therapeutic Agent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Angiogenesis Therapeutic Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Angiogenesis Therapeutic Agent Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Angiogenesis Therapeutic Agent Sales (k units) of Manufacturers (2021-2026)
Table 7. Global Angiogenesis Therapeutic Agent Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Angiogenesis Therapeutic Agent Revenue of Manufacturers (2021-2026)
Table 9. Global Angiogenesis Therapeutic Agent Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Angiogenesis Therapeutic Agent Average Price (US$/unit) of Manufacturers (2021-2026)
Table 11. Global Angiogenesis Therapeutic Agent Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Angiogenesis Therapeutic Agent, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Angiogenesis Therapeutic Agent, Product Type & Application
Table 14. Global Angiogenesis Therapeutic Agent Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Angiogenesis Therapeutic Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Sun Pharma Company Information
Table 19. Sun Pharma Business Overview
Table 20. Sun Pharma Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 21. Sun Pharma Angiogenesis Therapeutic Agent Product Portfolio
Table 22. Sun Pharma Recent Developments
Table 23. Shanghai Pharmaceuticals Company Information
Table 24. Shanghai Pharmaceuticals Business Overview
Table 25. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 26. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolio
Table 27. Shanghai Pharmaceuticals Recent Developments
Table 28. Johnson & Johnson Company Information
Table 29. Johnson & Johnson Business Overview
Table 30. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 31. Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolio
Table 32. Johnson & Johnson Recent Developments
Table 33. Novartis AG Company Information
Table 34. Novartis AG Business Overview
Table 35. Novartis AG Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 36. Novartis AG Angiogenesis Therapeutic Agent Product Portfolio
Table 37. Novartis AG Recent Developments
Table 38. Gilead Sciences, Inc. Company Information
Table 39. Gilead Sciences, Inc. Business Overview
Table 40. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 41. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolio
Table 42. Gilead Sciences, Inc. Recent Developments
Table 43. Pfizer Company Information
Table 44. Pfizer Business Overview
Table 45. Pfizer Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 46. Pfizer Angiogenesis Therapeutic Agent Product Portfolio
Table 47. Pfizer Recent Developments
Table 48. Daiichi Sankyo Company Information
Table 49. Daiichi Sankyo Business Overview
Table 50. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 51. Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolio
Table 52. Daiichi Sankyo Recent Developments
Table 53. Bayer AG Company Information
Table 54. Bayer AG Business Overview
Table 55. Bayer AG Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 56. Bayer AG Angiogenesis Therapeutic Agent Product Portfolio
Table 57. Bayer AG Recent Developments
Table 58. The Geuder Group, MORCHER GmbH Company Information
Table 59. The Geuder Group, MORCHER GmbH Business Overview
Table 60. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 61. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolio
Table 62. The Geuder Group, MORCHER GmbH Recent Developments
Table 63. Santen Pharmaceutical Co., Ltd. Company Information
Table 64. Santen Pharmaceutical Co., Ltd. Business Overview
Table 65. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 66. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolio
Table 67. Santen Pharmaceutical Co., Ltd. Recent Developments
Table 68. Regeneron Pharmaceuticals, Inc. Company Information
Table 69. Regeneron Pharmaceuticals, Inc. Business Overview
Table 70. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 71. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolio
Table 72. Regeneron Pharmaceuticals, Inc. Recent Developments
Table 73. Otsuka Pharmaceutical Co. Ltd Company Information
Table 74. Otsuka Pharmaceutical Co. Ltd Business Overview
Table 75. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 76. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolio
Table 77. Otsuka Pharmaceutical Co. Ltd Recent Developments
Table 78. Novamedika Company Information
Table 79. Novamedika Business Overview
Table 80. Novamedika Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 81. Novamedika Angiogenesis Therapeutic Agent Product Portfolio
Table 82. Novamedika Recent Developments
Table 83. Medicom Health care Company Information
Table 84. Medicom Health care Business Overview
Table 85. Medicom Health care Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 86. Medicom Health care Angiogenesis Therapeutic Agent Product Portfolio
Table 87. Medicom Health care Recent Developments
Table 88. Implandata ophthalmic products GmbH Company Information
Table 89. Implandata ophthalmic products GmbH Business Overview
Table 90. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 91. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolio
Table 92. Implandata ophthalmic products GmbH Recent Developments
Table 93. Genentech, Inc. Company Information
Table 94. Genentech, Inc. Business Overview
Table 95. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 96. Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolio
Table 97. Genentech, Inc. Recent Developments
Table 98. Eyetech Inc. Company Information
Table 99. Eyetech Inc. Business Overview
Table 100. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 101. Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolio
Table 102. Eyetech Inc. Recent Developments
Table 103. ERC Labs Company Information
Table 104. ERC Labs Business Overview
Table 105. ERC Labs Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 106. ERC Labs Angiogenesis Therapeutic Agent Product Portfolio
Table 107. ERC Labs Recent Developments
Table 108. Becton, Dickinson and Company Company Information
Table 109. Becton, Dickinson and Company Business Overview
Table 110. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 111. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolio
Table 112. Becton, Dickinson and Company Recent Developments
Table 113. Allergan plc Company Information
Table 114. Allergan plc Business Overview
Table 115. Allergan plc Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 116. Allergan plc Angiogenesis Therapeutic Agent Product Portfolio
Table 117. Allergan plc Recent Developments
Table 118. Global Angiogenesis Therapeutic Agent Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 119. Global Angiogenesis Therapeutic Agent Sales by Region (2021-2026) & (k units)
Table 120. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2021-2026)
Table 121. Global Angiogenesis Therapeutic Agent Sales by Region (2027-2032) & (k units)
Table 122. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2027-2032)
Table 123. Global Angiogenesis Therapeutic Agent Revenue by Region (2021-2026) & (US$ Million)
Table 124. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2021-2026)
Table 125. Global Angiogenesis Therapeutic Agent Revenue by Region (2027-2032) & (US$ Million)
Table 126. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2027-2032)
Table 127. North America Angiogenesis Therapeutic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 128. North America Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units)
Table 129. North America Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units)
Table 130. North America Angiogenesis Therapeutic Agent Revenue by Country (2021-2026) & (US$ Million)
Table 131. North America Angiogenesis Therapeutic Agent Revenue by Country (2027-2032) & (US$ Million)
Table 132. Europe Angiogenesis Therapeutic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 133. Europe Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units)
Table 134. Europe Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units)
Table 135. Europe Angiogenesis Therapeutic Agent Revenue by Country (2021-2026) & (US$ Million)
Table 136. Europe Angiogenesis Therapeutic Agent Revenue by Country (2027-2032) & (US$ Million)
Table 137. Asia Pacific Angiogenesis Therapeutic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 138. Asia Pacific Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units)
Table 139. Asia Pacific Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units)
Table 140. Asia Pacific Angiogenesis Therapeutic Agent Revenue by Country (2021-2026) & (US$ Million)
Table 141. Asia Pacific Angiogenesis Therapeutic Agent Revenue by Country (2027-2032) & (US$ Million)
Table 142. South America Angiogenesis Therapeutic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 143. South America Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units)
Table 144. South America Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units)
Table 145. South America Angiogenesis Therapeutic Agent Revenue by Country (2021-2026) & (US$ Million)
Table 146. South America Angiogenesis Therapeutic Agent Revenue by Country (2027-2032) & (US$ Million)
Table 147. Middle East and Africa Angiogenesis Therapeutic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 148. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units)
Table 149. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2027-2032) & (k units)
Table 150. Middle East and Africa Angiogenesis Therapeutic Agent Revenue by Country (2021-2026) & (US$ Million)
Table 151. Middle East and Africa Angiogenesis Therapeutic Agent Revenue by Country (2027-2032) & (US$ Million)
Table 152. Global Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (k units)
Table 153. Global Angiogenesis Therapeutic Agent Sales by Type (2027-2032) & (k units)
Table 154. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2021-2026)
Table 155. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2027-2032)
Table 156. Global Angiogenesis Therapeutic Agent Revenue by Type (2021-2026) & (US$ Million)
Table 157. Global Angiogenesis Therapeutic Agent Revenue by Type (2027-2032) & (US$ Million)
Table 158. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2021-2026)
Table 159. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2027-2032)
Table 160. Global Angiogenesis Therapeutic Agent Price by Type (2021-2026) & (US$/unit)
Table 161. Global Angiogenesis Therapeutic Agent Price by Type (2027-2032) & (US$/unit)
Table 162. Global Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (k units)
Table 163. Global Angiogenesis Therapeutic Agent Sales by Application (2027-2032) & (k units)
Table 164. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2021-2026)
Table 165. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2027-2032)
Table 166. Global Angiogenesis Therapeutic Agent Revenue by Application (2021-2026) & (US$ Million)
Table 167. Global Angiogenesis Therapeutic Agent Revenue by Application (2027-2032) & (US$ Million)
Table 168. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2021-2026)
Table 169. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2027-2032)
Table 170. Global Angiogenesis Therapeutic Agent Price by Application (2021-2026) & (US$/unit)
Table 171. Global Angiogenesis Therapeutic Agent Price by Application (2027-2032) & (US$/unit)
Table 172. Key Raw Materials
Table 173. Raw Materials Key Suppliers
Table 174. Angiogenesis Therapeutic Agent Distributors List
Table 175. Angiogenesis Therapeutic Agent Customers List
Table 176. Angiogenesis Therapeutic Agent Industry Trends
Table 177. Angiogenesis Therapeutic Agent Industry Drivers
Table 178. Angiogenesis Therapeutic Agent Industry Restraints
Table 179. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Angiogenesis Therapeutic Agent Product Image
Figure 5. Global Angiogenesis Therapeutic Agent Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Angiogenesis Therapeutic Agent Market Size (2021-2032) & (US$ Million)
Figure 7. Global Angiogenesis Therapeutic Agent Sales (2021-2032) & (k units)
Figure 8. Global Angiogenesis Therapeutic Agent Average Price (US$/unit) & (2021-2032)
Figure 9. Diabetic Retinopathy Product Image
Figure 10. Myopic Choroidal Neovascularization Product Image
Figure 11. Macular Edema Product Image
Figure 12. Macular Degeneration Product Image
Figure 13. Online Pharmacies Product Image
Figure 14. Hospital Pharmacies Product Image
Figure 15. Retail Pharmacies Product Image
Figure 16. Global Angiogenesis Therapeutic Agent Revenue Share by Manufacturers in 2025
Figure 17. Global Manufacturers of Angiogenesis Therapeutic Agent, Manufacturing Sites & Headquarters
Figure 18. Global Top 5 and 10 Angiogenesis Therapeutic Agent Players Market Share by Revenue in 2025
Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 20. Global Angiogenesis Therapeutic Agent Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 21. Global Angiogenesis Therapeutic Agent Sales by Region in 2025
Figure 22. Global Angiogenesis Therapeutic Agent Revenue by Region in 2025
Figure 23. North America Angiogenesis Therapeutic Agent Market Size by Country in 2025
Figure 24. North America Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2032)
Figure 25. North America Angiogenesis Therapeutic Agent Revenue Market Share by Country (2021-2032)
Figure 26. United States Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 27. Canada Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 28. Mexico Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Europe Angiogenesis Therapeutic Agent Market Size by Country in 2025
Figure 30. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2032)
Figure 31. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Country (2021-2032)
Figure 32. Germany Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. France Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. U.K. Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. Italy Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Russia Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Spain Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Netherlands Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Switzerland Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Sweden Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Poland Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. Asia Pacific Angiogenesis Therapeutic Agent Market Size by Country in 2025
Figure 43. Asia Pacific Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2032)
Figure 44. Asia Pacific Angiogenesis Therapeutic Agent Revenue Market Share by Country (2021-2032)
Figure 45. China Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. Japan Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. South Korea Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. India Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Australia Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Taiwan Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Southeast Asia Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Southeast Asia Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. South America Angiogenesis Therapeutic Agent Market Size by Country in 2025
Figure 54. South America Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2032)
Figure 55. South America Angiogenesis Therapeutic Agent Revenue Market Share by Country (2021-2032)
Figure 56. Brazil Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. Argentina Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Chile Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. Middle East and Africa Angiogenesis Therapeutic Agent Market Size by Country in 2025
Figure 60. Middle East and Africa Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2032)
Figure 61. Middle East and Africa Angiogenesis Therapeutic Agent Revenue Market Share by Country (2021-2032)
Figure 62. Egypt Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 63. South Africa Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 64. Israel Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 65. Türkiye Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 66. GCC Countries Angiogenesis Therapeutic Agent Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 67. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2021-2032)
Figure 68. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2021-2032)
Figure 69. Global Angiogenesis Therapeutic Agent Price (US$/unit) by Type (2021-2032)
Figure 70. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2021-2032)
Figure 71. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2021-2032)
Figure 72. Global Angiogenesis Therapeutic Agent Price (US$/unit) by Application (2021-2032)
Figure 73. Angiogenesis Therapeutic Agent Value Chain
Figure 74. Angiogenesis Therapeutic Agent Production Mode & Process
Figure 75. Direct Comparison with Distribution Share
Figure 76. Distributors Profiles
Figure 77. Angiogenesis Therapeutic Agent Industry Opportunities and Challenges
Scope & coverage.
Types
- Diabetic Retinopathy
- Myopic Choroidal Neovascularization
- Macular Edema
- Macular Degeneration
Applications
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Companies covered
- Sun Pharma
- Shanghai Pharmaceuticals
- Johnson & Johnson
- Novartis AG
- Gilead Sciences, Inc.
- Pfizer
- Daiichi Sankyo
- Bayer AG
- The Geuder Group, MORCHER GmbH
- Santen Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Otsuka Pharmaceutical Co. Ltd
- Novamedika
- Medicom Health care
- Implandata ophthalmic products GmbH
- Genentech, Inc.
- Eyetech Inc.
- ERC Labs
- Becton, Dickinson and Company
- Allergan plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Angiogenesis Therapeutic Agent Market Size (2021-2032)
- 2.2.2 Global Angiogenesis Therapeutic Agent Sales (2021-2032)
- 2.2.3 Global Angiogenesis Therapeutic Agent Market Average Price (2021-2032)
- 2.3 Angiogenesis Therapeutic Agent by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Diabetic Retinopathy
- 2.3.3 Myopic Choroidal Neovascularization
- 2.3.4 Macular Edema
- 2.3.5 Macular Degeneration
- 2.4 Angiogenesis Therapeutic Agent by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Online Pharmacies
- 2.4.3 Hospital Pharmacies
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Angiogenesis Therapeutic Agent Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Angiogenesis Therapeutic Agent Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Angiogenesis Therapeutic Agent Revenue of Manufacturers (2021-2026)
- 3.4 Global Angiogenesis Therapeutic Agent Average Price by Manufacturers (2021-2026)
- 3.5 Global Angiogenesis Therapeutic Agent Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Angiogenesis Therapeutic Agent, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Angiogenesis Therapeutic Agent, Product Type & Application
- 3.8 Global Manufacturers of Angiogenesis Therapeutic Agent, Established Date
- 3.9 Global Angiogenesis Therapeutic Agent Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sun Pharma
- 4.1.1 Sun Pharma Company Information
- 4.1.2 Sun Pharma Business Overview
- 4.1.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sun Pharma Angiogenesis Therapeutic Agent Product Portfolio
- 4.1.5 Sun Pharma Recent Developments
- 4.2 Shanghai Pharmaceuticals
- 4.2.1 Shanghai Pharmaceuticals Company Information
- 4.2.2 Shanghai Pharmaceuticals Business Overview
- 4.2.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolio
- 4.2.5 Shanghai Pharmaceuticals Recent Developments
- 4.3 Johnson & Johnson
- 4.3.1 Johnson & Johnson Company Information
- 4.3.2 Johnson & Johnson Business Overview
- 4.3.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolio
- 4.3.5 Johnson & Johnson Recent Developments
- 4.4 Novartis AG
- 4.4.1 Novartis AG Company Information
- 4.4.2 Novartis AG Business Overview
- 4.4.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis AG Angiogenesis Therapeutic Agent Product Portfolio
- 4.4.5 Novartis AG Recent Developments
- 4.5 Gilead Sciences, Inc.
- 4.5.1 Gilead Sciences, Inc. Company Information
- 4.5.2 Gilead Sciences, Inc. Business Overview
- 4.5.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolio
- 4.5.5 Gilead Sciences, Inc. Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Angiogenesis Therapeutic Agent Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Daiichi Sankyo
- 4.7.1 Daiichi Sankyo Company Information
- 4.7.2 Daiichi Sankyo Business Overview
- 4.7.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolio
- 4.7.5 Daiichi Sankyo Recent Developments
- 4.8 Bayer AG
- 4.8.1 Bayer AG Company Information
- 4.8.2 Bayer AG Business Overview
- 4.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bayer AG Angiogenesis Therapeutic Agent Product Portfolio
- 4.8.5 Bayer AG Recent Developments
- 4.9 The Geuder Group, MORCHER GmbH
- 4.9.1 The Geuder Group, MORCHER GmbH Company Information
- 4.9.2 The Geuder Group, MORCHER GmbH Business Overview
- 4.9.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolio
- 4.9.5 The Geuder Group, MORCHER GmbH Recent Developments
- 4.10 Santen Pharmaceutical Co., Ltd.
- 4.10.1 Santen Pharmaceutical Co., Ltd. Company Information
- 4.10.2 Santen Pharmaceutical Co., Ltd. Business Overview
- 4.10.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolio
- 4.10.5 Santen Pharmaceutical Co., Ltd. Recent Developments
- 4.11 Regeneron Pharmaceuticals, Inc.
- 4.11.1 Regeneron Pharmaceuticals, Inc. Company Information
- 4.11.2 Regeneron Pharmaceuticals, Inc. Business Overview
- 4.11.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolio
- 4.11.5 Regeneron Pharmaceuticals, Inc. Recent Developments
- 4.12 Otsuka Pharmaceutical Co. Ltd
- 4.12.1 Otsuka Pharmaceutical Co. Ltd Company Information
- 4.12.2 Otsuka Pharmaceutical Co. Ltd Business Overview
- 4.12.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolio
- 4.12.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
- 4.13 Novamedika
- 4.13.1 Novamedika Company Information
- 4.13.2 Novamedika Business Overview
- 4.13.3 Novamedika Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Novamedika Angiogenesis Therapeutic Agent Product Portfolio
- 4.13.5 Novamedika Recent Developments
- 4.14 Medicom Health care
- 4.14.1 Medicom Health care Company Information
- 4.14.2 Medicom Health care Business Overview
- 4.14.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Medicom Health care Angiogenesis Therapeutic Agent Product Portfolio
- 4.14.5 Medicom Health care Recent Developments
- 4.15 Implandata ophthalmic products GmbH
- 4.15.1 Implandata ophthalmic products GmbH Company Information
- 4.15.2 Implandata ophthalmic products GmbH Business Overview
- 4.15.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolio
- 4.15.5 Implandata ophthalmic products GmbH Recent Developments
- 4.16 Genentech, Inc.
- 4.16.1 Genentech, Inc. Company Information
- 4.16.2 Genentech, Inc. Business Overview
- 4.16.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolio
- 4.16.5 Genentech, Inc. Recent Developments
- 4.17 Eyetech Inc.
- 4.17.1 Eyetech Inc. Company Information
- 4.17.2 Eyetech Inc. Business Overview
- 4.17.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolio
- 4.17.5 Eyetech Inc. Recent Developments
- 4.18 ERC Labs
- 4.18.1 ERC Labs Company Information
- 4.18.2 ERC Labs Business Overview
- 4.18.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 ERC Labs Angiogenesis Therapeutic Agent Product Portfolio
- 4.18.5 ERC Labs Recent Developments
- 4.19 Becton, Dickinson and Company
- 4.19.1 Becton, Dickinson and Company Company Information
- 4.19.2 Becton, Dickinson and Company Business Overview
- 4.19.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolio
- 4.19.5 Becton, Dickinson and Company Recent Developments
- 4.20 Allergan plc
- 4.20.1 Allergan plc Company Information
- 4.20.2 Allergan plc Business Overview
- 4.20.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Allergan plc Angiogenesis Therapeutic Agent Product Portfolio
- 4.20.5 Allergan plc Recent Developments
5 Global Angiogenesis Therapeutic Agent Market Scenario by Region
- 5.1 Global Angiogenesis Therapeutic Agent Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Angiogenesis Therapeutic Agent Sales by Region: 2021-2032
- 5.2.1 Global Angiogenesis Therapeutic Agent Sales by Region: 2021-2026
- 5.2.2 Global Angiogenesis Therapeutic Agent Sales by Region: 2027-2032
- 5.3 Global Angiogenesis Therapeutic Agent Revenue by Region: 2021-2032
- 5.3.1 Global Angiogenesis Therapeutic Agent Revenue by Region: 2021-2026
- 5.3.2 Global Angiogenesis Therapeutic Agent Revenue by Region: 2027-2032
- 5.4 North America Angiogenesis Therapeutic Agent Market Facts & Figures by Country
- 5.4.1 North America Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
- 5.4.3 North America Angiogenesis Therapeutic Agent Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Angiogenesis Therapeutic Agent Market Facts & Figures by Country
- 5.5.1 Europe Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
- 5.5.3 Europe Angiogenesis Therapeutic Agent Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Angiogenesis Therapeutic Agent Market Facts & Figures by Country
- 5.6.1 Asia Pacific Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Angiogenesis Therapeutic Agent Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Angiogenesis Therapeutic Agent Market Facts & Figures by Country
- 5.7.1 South America Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
- 5.7.3 South America Angiogenesis Therapeutic Agent Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Angiogenesis Therapeutic Agent Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Angiogenesis Therapeutic Agent Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Angiogenesis Therapeutic Agent Sales by Type (2021-2032)
- 6.1.1 Global Angiogenesis Therapeutic Agent Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2021-2032)
- 6.2 Global Angiogenesis Therapeutic Agent Revenue by Type (2021-2032)
- 6.2.1 Global Angiogenesis Therapeutic Agent Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2021-2032)
- 6.3 Global Angiogenesis Therapeutic Agent Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Angiogenesis Therapeutic Agent Sales by Application (2021-2032)
- 7.1.1 Global Angiogenesis Therapeutic Agent Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2021-2032)
- 7.2 Global Angiogenesis Therapeutic Agent Revenue by Application (2021-2032)
- 7.2.1 Global Angiogenesis Therapeutic Agent Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2021-2032)
- 7.3 Global Angiogenesis Therapeutic Agent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Angiogenesis Therapeutic Agent Value Chain Analysis
- 8.1.1 Angiogenesis Therapeutic Agent Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Angiogenesis Therapeutic Agent Production Mode & Process
- 8.2 Angiogenesis Therapeutic Agent Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Angiogenesis Therapeutic Agent Distributors
- 8.2.3 Angiogenesis Therapeutic Agent Customers
9 Global Angiogenesis Therapeutic Agent Analyzing Market Dynamics
- 9.1 Angiogenesis Therapeutic Agent Industry Trends
- 9.2 Angiogenesis Therapeutic Agent Industry Drivers
- 9.3 Angiogenesis Therapeutic Agent Industry Opportunities and Challenges
- 9.4 Angiogenesis Therapeutic Agent Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst